Oxidative phosphorylation dysfunction modulates expression of extracellular matrix--remodeling genes and invasion.
A number of recent studies suggest that mitochondrial function is a player in tumor development and progression. In this study, we have used gene expression arrays to examine transcriptional differences between oxidative phosphorylation (OXPHOS)-competent and OXPHOS-impaired human osteosarcoma cells. Genes associated with extracellular matrix remodeling, including members of the matrix metalloproteinases (MMPs) and tissue inhibitors of the MMP (TIMP) family, urokinase plasminogen activator and its inhibitor plasminogen-activator inhibitor-1 (PAI1), and CTGF and CYR61 (members of the Cysteine-rich 61, Connective Tissue Growth Factor and Nephroblastoma-overexpressed (CCN) gene family of growth regulators), were among the ones significantly altered in the OXPHOS-deficient cells. These changes were confirmed by RT-PCR and promoter reporter assays. Alterations at the protein level for some of these factors were also observed, though at a lower magnitude, with the exception of TIMP1, where a marked change in steady-state levels of the protein was observed after induction of OXPHOS dysfunction. Repopulation of mitochondrial DNA (mtDNA)-less cells with wild-type mtDNA reduced matrigel invasion, whereas repopulation with a mutated mtDNA did not. Taken together our data suggests that OXPHOS dysfunction modulates the invasive phenotype by transcriptional regulation of genes coding for members of the MMP/TIMP system, urokinase plasminogen activator/plasminogen-activator inhibitor I and CCN proteins.
van Waveren
Corina
C
Department of Cell Biology and Anatomy, University of Miami School of Medicine, Miami, FL 33136, USA.
Sun
Yubo
Y
Cheung
Herman S
HS
Moraes
Carlos T
CT
D001859:Bone Neoplasms / Q000235:genetics* / Q000473:pathology; D055513:Connective Tissue Growth Factor; D055515:Cysteine-Rich Protein 61; D005109:Extracellular Matrix / Q000378:metabolism*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017874:Immediate-Early Proteins / Q000096:biosynthesis; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis; D020782:Matrix Metalloproteinases / Q000096:biosynthesis; D008928:Mitochondria / Q000502:physiology; D009361:Neoplasm Invasiveness / Q000235:genetics*; D012516:Osteosarcoma / Q000235:genetics* / Q000473:pathology; D010085:Oxidative Phosphorylation; D010641:Phenotype; D015849:Plasminogen Inactivators / Q000096:biosynthesis; D011480:Protease Inhibitors; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis
C501848:CCN1 protein, human; C526317:CCN2 protein, human; D055515:Cysteine-Rich Protein 61; D017874:Immediate-Early Proteins; D036341:Intercellular Signaling Peptides and Proteins; D015849:Plasminogen Inactivators; D011480:Protease Inhibitors; D055513:Connective Tissue Growth Factor; D014568:Urokinase-Type Plasminogen Activator; D020782:Matrix Metalloproteinases